Navigation

Ensure Drug Quality and Safety – “Academic Detailing”

While DC Delays, States Move Forward on Health Care Reforms

As Congress delays moving forward on the passage of comprehensive health care reform, progressive state leaders from across the country have been demanding passage of reform as critical for families across the nation.  But that doesn't mean they are waiting; state leaders are moving forward, laying the groundwork for how national changes should be implemented, and creating the momentum for other meaningful health care reforms in their states.

"Prescriber Education Service" - Ensure Safety and Accuracy in Prescribing Decisions: Key Facts, Polling, Best Practices

Policy Overview: Establish a Prescriber Education Program, or “academic detailing” initiative, for the dissemination of scientific and clinical data about the effectiveness and costs of pharmaceuticals and medical devices. Such a program can reduce state health care costs and improve medical quality. States have several options for funding education programs outside of the general fund, including a fee on manufacturers and federal grants.

Rx Reforms to Address Budget Deficits and Ensure Quality of Medications

As part of our Shared Multi-State Agenda, the Progressive States Network is working with legislators, advocates and leading experts to promote Rx reforms in 2010 that will reduce health care costs for consumers, businesses, and state and local governments, and will help ensure access to safe and effective medications.  Through coordinated, strategic support, PSN and our allies will be working to introduce and advance Rx reforms that will help address state budget deficits and improve access to quality medications in as many states possible; providing model legislation, policy analysis, messaging and more - all of which has been gathered and will be constantly updated on our Prescription Drug Reform Shared Agenda web page.

Prescription Drug Marketing and Safety Policy Guide

Policy Overview: To reap its record profits and drive up costs for families, businesses, and government health programs, the pharmaceutical industry markets the most expensive “celebrity” drugs over other medications that are equally or more effective and less costly.

The Supreme Court and the States 2008-2009: Trend Defending State Authority Emerges this Term

Whether out of circumstance or an emerging trend, where state authority was at issue, this term the U.S. Supreme Court overwhelmingly deferred to state decision makers-- a significant reveral from last year. 

States' Victory Against Preemption - FDA Approval Does not Block State Tort Claims Against Drug Makers

In a much anticipated decision, Wyeth v. Levine, the Supreme Court in a 6-3 decision upheld states' right to hold the drug industry accountable for not adequately warning consumers and prescribers of a drug's impact.  The pharmaceutical industry had argued that Federal Drug Administration approval of a drug's warning label pre-empts state claims of injury based on the failure by a company to warn of additional dangers not covered by the FDA-approved label.  The court rejected this argument.

Health Care for All: Policy Options for 2009

Download a copy of the report in PDF format here.  View the HTML version of the report here.